Akeso clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-19
What changed in the last 30 days
3 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 2 with minor changes only.
- Notable: AK146D1 as Monotherapy and in Combination With AK104 or AK112, · Advanced Solid Tumors Primary completion pushed from Nov 5, 2026 to Jun 30, 2028
- Minor: Subcutaneous Injection of Ebronucimab in Chinese Healthy Male Subjects Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Not Yet Recruiting
- Minor: Label,Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 · Advanced Malignant Tumors Trial completed
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New trial filings, last 30 days
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-11-16 | NCT07939919 A Study of AK158D1 in Advanced Solid Tumors | Phase 1 | Not Yet Recruiting |
Active trials by phase
| Phase 1 | 15 | |
| Phase 1/2 | 18 | |
| Phase 2 | 26 | |
| Phase 3 | 23 |
Not charted: 1 active trial with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Disease areas by active trials, top 10 of 23
Lung Cancer (15) · Non-Small Cell Lung Cancer (NSCLC) (13) · Colorectal Cancer (6) · Liver Cancer (6) · Pancreatic Cancer (5) · Breast Cancer (4) · Atopic Dermatitis (3) · Gastric Cancer (3) · Head & Neck Cancer (3) · Acute Myeloid Leukemia (AML) (2)
Get alerts when Akeso's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.